UOC
INZY

UBS O'Connor’s Inozyme Pharma INZY Stock Holding History

UBS O'Connor’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,788
Closed -$31.7K – 421
2025
Q1 		$31.7K Sell
34,788
-166,444
-83% -$231K ﹤0.01% 294
2024
Q4 		$557K Sell
201,232
-25,000
-11% -$95.1K 0.01% 272
2024
Q3 		$1.18M Buy
226,232
+21,014
+10% +$109K 0.03% 257
2024
Q2 		$915K Buy
205,218
+22,000
+12% +$107K 0.03% 308
2024
Q1 		$1.4M Sell
183,218
-61,710
-25% -$339K 0.04% 240
2023
Q4 		$1.04M Buy
244,928
+89,623
+58% +$318K 0.03% 265
2023
Q3 		$652K Hold
155,305
– – 0.01% 370
2023
Q2 		$865K Buy
155,305
+7,651
+5% +$45.2K 0.02% 398
2023
Q1 		$846K Buy
+147,654
New +$390K 0.02% 427
2022
Q4 		– Sell
-165,498
Closed -$444K – 160
2022
Q3 		$444K Sell
165,498
-5,849
-3% -$21.2K 0.01% 816
2022
Q2 		$817K Buy
+171,347
New +$745K 0.01% 784

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

UBS O'Connor's INZY Position: Q2 2025 in Review

UBS O'Connor sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 34,788 shares — an estimated $31.7K sold.

UBS O'Connor first reported a position in INZY in Q2 2022 and held it in 11 quarters. The position peaked at $1.4M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • UBS O'Connor reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 34,788 Inozyme Pharma shares in Q2 2025, an estimated $31.7K.
  • UBS O'Connor first reported a position in Inozyme Pharma in Q2 2022 and held it in 11 quarters.
  • UBS O'Connor's Inozyme Pharma position peaked at $1.4M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.